Global Central Nervous System (CNS) Stimulant Drugs Market Report 2019-2023 – Rising Demand to Legalize Cannabis Worldwide is a Key Market Driver – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Central Nervous System (CNS) Stimulant Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The rise in CNS disorders

CNS disorders such as sleep apnea, narcolepsy, and attention-deficit hyperactivity disorder have witnessed a significant rise in recent years. Attention-deficit hyperactivity disorder interferes with the functioning and development of a person. This increasing prevalence of CNS disorders will lead to the expansion of the global central nervous system stimulant drugs market at a CAGR of over 5% during the forecast period.

Rising demand to legalize cannabis worldwide

Cannabis can increase the dopamine level in the brain and is used widely in the treatment of attention-deficit hyperactivity disorder. According to researcher’s synthetic cannabis may have benefits on people with sleep apnea due to the modulatory effects of these drugs on serotonin-mediated apneas. This demand to legalize cannabis across the world is expected to have a positive impact on the overall market growth.

Market Dynamics

The report looks at factors such as rise in CNS disorders, approval of new stimulants, and increasing use of stimulants worldwide. However, numerous side effects of drugs, development of the first-in-class therapeutics, and increasing demand for non-pharmacological therapies may hamper the growth of the central nervous system stimulant drugs industry over the forecast period.

Segment Coverage

The central nervous system stimulant drugs market analysis considers sales from attention-deficit hyperactivity disorder, narcolepsy, and others. This analysis also considers the sales of central nervous system stimulant drugs in Asia, Europe, North America, and RoW.

In 2018, the attention-deficit hyperactivity disorder segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing prevalence of this disorder among children and adolescents, easy availability of stimulants will play a significant role in the attention-deficit hyperactivity disorder segment to maintain its market position.

Competitive Landscape

With the presence of a few major players, the global central nervous system stimulant drugs market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several central nervous system stimulant drugs manufacturers that include:

• GlaxoSmithKline PLC
• Johnson & Johnson Services Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
  

Also, the central nervous system stimulant drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

• Comparison by application
• Attention-deficit hyperactivity disorder – Market size and forecast 2018-2023
• Narcolepsy – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• RoW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

• R&D of stimulants to treat attention-deficit hyperactivity disorder
• Rising demand to legalize cannabis worldwide
• Increasing repurposing of drugs

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• GlaxoSmithKline PLC
• Johnson & Johnson Services Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/6z5r6f

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Central Nervous System Drugs